288 related articles for article (PubMed ID: 23127332)
21. Paclitaxel-loaded polymeric micelles based on poly(ɛ-caprolactone)-poly(ethylene glycol)-poly(ɛ-caprolactone) triblock copolymers: in vitro and in vivo evaluation.
Zhang L; He Y; Ma G; Song C; Sun H
Nanomedicine; 2012 Aug; 8(6):925-34. PubMed ID: 22101107
[TBL] [Abstract][Full Text] [Related]
22. Photo-responsive and NGR-mediated multifunctional nanostructured lipid carrier for tumor-specific therapy.
Yang Y; Xie X; Yang Y; Zhang H; Mei X
J Pharm Sci; 2015 Apr; 104(4):1328-39. PubMed ID: 25630979
[TBL] [Abstract][Full Text] [Related]
23. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
[TBL] [Abstract][Full Text] [Related]
24. The theranostic efficiency of tumor-specific, pH-responsive, peptide-modified, liposome-containing paclitaxel and superparamagnetic iron oxide nanoparticles.
Zheng XC; Ren W; Zhang S; Zhong T; Duan XC; Yin YF; Xu MQ; Hao YL; Li ZT; Li H; Liu M; Li ZY; Zhang X
Int J Nanomedicine; 2018; 13():1495-1504. PubMed ID: 29559778
[TBL] [Abstract][Full Text] [Related]
25. PEGylated poly(trimethylene carbonate) nanoparticles loaded with paclitaxel for the treatment of advanced glioma: in vitro and in vivo evaluation.
Jiang X; Xin H; Sha X; Gu J; Jiang Y; Law K; Chen Y; Chen L; Wang X; Fang X
Int J Pharm; 2011 Nov; 420(2):385-94. PubMed ID: 21920419
[TBL] [Abstract][Full Text] [Related]
26. Targeted treatment of choroidal neovascularization using integrin-mediated sterically stabilized liposomes loaded with combretastatin A4.
Ma L; Liu YL; Ma ZZ; Dou HL; Xu JH; Wang JC; Zhang X; Zhang Q
J Ocul Pharmacol Ther; 2009 Jun; 25(3):195-200. PubMed ID: 19456253
[TBL] [Abstract][Full Text] [Related]
27. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy.
Yoshizawa Y; Kono Y; Ogawara K; Kimura T; Higaki K
Int J Pharm; 2011 Jun; 412(1-2):132-41. PubMed ID: 21507344
[TBL] [Abstract][Full Text] [Related]
28. CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels.
Hu Q; Gao X; Kang T; Feng X; Jiang D; Tu Y; Song Q; Yao L; Jiang X; Chen H; Chen J
Biomaterials; 2013 Dec; 34(37):9496-508. PubMed ID: 24054848
[TBL] [Abstract][Full Text] [Related]
29. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.
Di Paolo D; Pastorino F; Zuccari G; Caffa I; Loi M; Marimpietri D; Brignole C; Perri P; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M; Pagnan G
J Control Release; 2013 Sep; 170(3):445-51. PubMed ID: 23792118
[TBL] [Abstract][Full Text] [Related]
30. PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptide-doxorubicin conjugate for tumor-specific therapy.
Yang Y; Yang Y; Xie X; Cai X; Zhang H; Gong W; Wang Z; Mei X
Biomaterials; 2014 May; 35(14):4368-81. PubMed ID: 24565519
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer.
Cao Q; Li ZB; Chen K; Wu Z; He L; Neamati N; Chen X
Eur J Nucl Med Mol Imaging; 2008 Aug; 35(8):1489-98. PubMed ID: 18373091
[TBL] [Abstract][Full Text] [Related]
32. Synergistic antitumor effect of combining metronomic chemotherapy with adoptive cell immunotherapy in nude mice.
Shi S; Tao L; Song H; Chen L; Huang G
APMIS; 2014 May; 122(5):380-91. PubMed ID: 24628659
[TBL] [Abstract][Full Text] [Related]
33. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
Zheng YB; Shang BY; Li Y; Zhen YS
Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics, biodistribution, efficacy and safety of N-octyl-O-sulfate chitosan micelles loaded with paclitaxel.
Zhang C; Qu G; Sun Y; Wu X; Yao Z; Guo Q; Ding Q; Yuan S; Shen Z; Ping Q; Zhou H
Biomaterials; 2008 Mar; 29(9):1233-41. PubMed ID: 18093646
[TBL] [Abstract][Full Text] [Related]
35. NGR-modified pH-sensitive liposomes for controlled release and tumor target delivery of docetaxel.
Gu Z; Chang M; Fan Y; Shi Y; Lin G
Colloids Surf B Biointerfaces; 2017 Dec; 160():395-405. PubMed ID: 28965079
[TBL] [Abstract][Full Text] [Related]
36. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461
[TBL] [Abstract][Full Text] [Related]
37. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
Zhan C; Gu B; Xie C; Li J; Liu Y; Lu W
J Control Release; 2010 Apr; 143(1):136-42. PubMed ID: 20056123
[TBL] [Abstract][Full Text] [Related]
38. Tyroservatide-TPGS-paclitaxel liposomes: Tyroservatide as a targeting ligand for improving breast cancer treatment.
Jin X; Li M; Yin L; Zhou J; Zhang Z; Lv H
Nanomedicine; 2017 Apr; 13(3):1105-1115. PubMed ID: 27845234
[TBL] [Abstract][Full Text] [Related]
39. Anti-tumor activity of paclitaxel through dual-targeting lipoprotein-mimicking nanocarrier.
Chen C; Hu H; Qiao M; Zhao X; Wang Y; Chen K; Chen D
J Drug Target; 2015 May; 23(4):311-22. PubMed ID: 25539074
[TBL] [Abstract][Full Text] [Related]
40. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
